KineMed, Inc. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 31

KineMed, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “KineMed, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- KineMed, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of KineMed, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of KineMed, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the KineMed, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate KineMed, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of KineMed, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the KineMed, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with KineMed, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of KineMed, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
KineMed, Inc. Snapshot
KineMed, Inc. Overview
Key Information
Key Facts
KineMed, Inc. – Research and Development Overview
Key Therapeutic Areas
KineMed, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
KineMed, Inc. – Pipeline Products Glance
KineMed, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
KineMed, Inc. – Drug Profiles
Drug For Cognitive Impairment
Product Description
Mechanism of Action
R&D Progress
Noscapine
Product Description
Mechanism of Action
R&D Progress
KineMed, Inc. – Pipeline Analysis
KineMed, Inc. – Pipeline Products by Therapeutic Class
KineMed, Inc. Pipeline Products By Target
KineMed, Inc. – Pipeline Products by Route of Administration
KineMed, Inc. – Pipeline Products by Molecule Type
KineMed, Inc. - Dormant Projects
KineMed, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 11, 2007: KineMed Presents Preclinical Data for Investigational Agent Drugs For Cognitive Impairment Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Oct 11, 2007: KineMed Presents Preclinical Data for Investigational Agent Drugs For Cognitive Impairment Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Oct 11, 2007: KineMed Presents Preclinical Data For Investigational Agent Demonstrating Neurogenesis And Confirming Improvements In Behavioral Model
Aug 03, 2007: KineMed Completed $15 Million Offering of Convertible Notes Funds To Support Advancement of Lead Program KM-801 Into Clinical Testing in 2008
Financial Deals Landscape
KineMed, Inc., Deals Volume Summary, 2004 to YTD 2010
KineMed, Inc., Deals Summary By Region, 2004 to YTD 2010
KineMed, Inc., Deals Summary, 2004 to YTD 2010
KineMed, Inc. Detailed Deal Summary
KineMed Broadens Co-Development Agreement With Bristol-Myers Squibb
KineMed Enters Into Co-Development Agreement With Bristol-Myers Squibb
KineMed Enters Into Co-Development Agreement With Bayer HealthCare
KineMed Enters Into Collaboration Agreement With Merck
Licensing Agreements
KineMed Enters Into Licensing Agreement With Merck
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Charter Schools - Global Outlook
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Aerospace and Defence Industry - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report